U.S., March 18 -- ClinicalTrials.gov registry received information related to the study (NCT07477366) titled 'Study of CD19 t-haNK and NAI With Rituximab in Participants With Indolent Non-Hodgkin Lymphoma' on March 11.
Brief Summary: Open-Label, Phase 2 Chemotherapy-Free Study ofCD19 t-haNK and NAI in Combination With Rituximab in Participants With Relapsed/Refractory B-Cell Indolent Non-Hodgkin Lymphoma. 40 Participant will be screened for 20 subjects enrollment.
Study Start Date: April, 2026
Study Type: INTERVENTIONAL
Condition:
Relapsed B-Cell Non-Hodgkin Lymphoma
Intervention:
BIOLOGICAL: CD19 t-haNK- IV Administration
CD19-Directed Therapies: CD19-targeted therapies, are biologic agents specifically designed to recognize and el...